Natera Inc (NTRA)vsVertex Pharmaceuticals Inc (VRTX)

NTRA

Natera Inc

NASDAQ

$194.24

-11.64%

HEALTHCARE · Cap: $30.71B

VRTX

Vertex Pharmaceuticals Inc

NASDAQ

$429.82

+1.13%

HEALTHCARE · Cap: $107.87B

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Vertex Pharmaceuticals Inc generates 430% more annual revenue ($12.22B vs $2.31B). VRTX leads profitability with a 35.5% profit margin vs -9.0%. VRTX earns a higher WallStSmart Score of 66/100 (B-).

NTRA

Avoid

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 6.5

Piotroski: 4/9

VRTX

Strong Buy

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 6.7Quality: 8.0

Piotroski: 3/9Altman Z: 3.62

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for NTRA.

VRTXUndervalued (+57.2%)

Margin of Safety

+57.2%

Fair Value

$992.87

Current Price

$429.82

$563.05 discount

UndervaluedFair: $992.87Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NTRA1 strengths · Avg: 10.0/10

Revenue GrowthGrowth

39.8%10/10

Revenue surging 39.8% year-over-year

VRTX6 strengths · Avg: 9.7/10

Profit MarginProfitability

35.5%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability

38.1%10/10

Strong operational efficiency at 38.1%

EPS GrowthGrowth

61.4%10/10

Earnings expanding 61.4% YoY

Altman Z-ScoreHealth

3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality

$107.87B9/10

Large-cap with strong market position

Return on EquityProfitability

24.2%9/10

Every $100 of equity generates 24 in profit

Areas to Watch

NTRA4 concerns · Avg: 2.8/10

Price/BookValuation

15.8x4/10

Trading at 15.8x book value

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Return on EquityProfitability

-14.3%2/10

ROE of -14.3% — below average capital efficiency

Profit MarginProfitability

-9.0%1/10

Currently unprofitable

VRTX3 concerns · Avg: 3.7/10

PEG RatioValuation

2.104/10

Expensive relative to growth rate

P/E RatioValuation

25.3x4/10

Moderate valuation

Piotroski F-ScoreQuality

3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : NTRA

The strongest argument for NTRA centers on Revenue Growth. Revenue growth of 39.8% demonstrates continued momentum.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.

Bear Case : NTRA

The primary concerns for NTRA are Price/Book, EPS Growth, Return on Equity.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

NTRA profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.

NTRA carries more volatility with a beta of 1.57 — expect wider price swings.

NTRA is growing revenue faster at 39.8% — sustainability is the question.

VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (66/100 vs 31/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Natera Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Compare with Other DIAGNOSTICS & RESEARCH Stocks

NTRA vs TMO NTRA vs DHR NTRA vs IDXX NTRA vs WAT NTRA vs A VRTX vs TMO VRTX vs DHR VRTX vs IDXX VRTX vs WAT VRTX vs A

Want to dig deeper into these stocks?

Full NTRA Analysis →Full VRTX Analysis →